Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Widespread application of intralesional tritiated thymidine injection to obtain cell kinetic data in lung cancer is described. Thymidine-labeling indices were obtained in 28 patients with lung cancer, and the data analyzed by histologic cell types. The mean and median labeling indices were highest in small-cell carcinoma of the lung. Mean values were significantly higher in the small-cell and in the large-cell undifferentiated carcinoma groups than in the adenocarcinoma and epidermoid carcinoma. On the other hand, a labeled mitosis curve in a patient with small-cell carcinoma yielded a duration of DNA synthesis of 18.8 h; not unlike those obtained for other solid tumors. According to our concepts of tumor growth, these findings suggest that the fraction of proliferating cells may be significantly higher in the small-cell and large-cell undifferentiated carcinomas than in the more differentiated cell types of bronchogenic cancer. Knowledge of the growth fraction of these cancers may have implications in directing therapeutic approaches and in interpreting features of the natural history of the disease.
 ...
PMID:Cell kinetic studies in patients with lung cancer. 446 59

For the study described in the paper, the effects of 10 days' chemotherapy with cefotaxime, clindamycin, mezlocillin, and piperacillin on local tumor growth and on spontaneous or artificial metastatic spread into the lungs were studied. For the animal tumor model Balb/c mice and the mouse sarcoma L-1 tumor were used. Chemotherapy was administered before, immediately after, or some time after the injection of tumor cells. The antibiotic dosage given to mice was calculated on a body weight basis from the doses recommended for humans. Cefotaxime and clindamycin did not influence the animal tumor model, whereas mezlocillin and piperacillin showed positive or negative effects depending on the chemotherapy schedule. In vitro none of the four antibiotics caused cytotoxic activity in cell cultures of mouse sarcoma L-1, human lung cancer E-14, or human malignant melanoma MEW.
 ...
PMID:Effects of cefotaxime, clindamycin, mezlocillin, and piperacillin on mouse sarcoma L-1 tumor. 609 92

Enhanced nucleocytoplasmic RNA transport has been demonstrated by incubating normal rat liver nuclei in presence of cytosols originating from the poorly differentiated, fast-growing hepatoma HW-165, in the linear phase of tumor growth. The effect of hepatoma HW-165 cytosol was reduced or suppressed in presence of small amounts of normal liver cytosol: on the other hand, several polypeptides of molecular weight 20,000 to 40,000 daltons were hardly detectable in hepatoma HW-165 cytosol, both arguments indicating that potentially regulatory proteins should be absent or present in reduced concentration in hepatoma HW-165 cytosol. No modification of RNA release was observed in presence of cytosols originating from the thymus of RNA virus (BL/F)-infected rats, whatever be the time after inoculation. Attempts were made to use the nuclear restriction assay, supplemented with plasma or serum of various origins, as a biochemical marker of neoplasia. In a first series of assays, including 80 cancer patients and 12 healthy controls, the RNA transport activity was stimulated by the serum of patients bearing various tumors (lung cancer, cancer of the respiratory tract, uterine cervix...), except in a few cases of mammary carcinoma, where values equivalent to or lower than the controls were obtained.
 ...
PMID:On the altered nucleocytoplasmic transport "in vitro" of rapidly labelled RNA, in the presence of cytosol or serum from tumor-bearing rats. 616 10

Twenty three cases of dimorphous lung cancer are analysed. There were found some specific features of the clinico-morphological picture of the neoplastic process in question: slow development, a predominant peripheral tumor growth, large size tumors, less pronounced local invasion of dimorphous cancer, comparatively rare metastases (34.8%). Three variants were distinguished in the combination of squamous cell and glandular foci: adenoepidermoid, squamous cell and mucoepidermoid ones.
 ...
PMID:[Clinical morphological characteristics of dimorphic lung cancer]. 625 36

Fifteen tumor-containing specimens were obtained directly from patients with small cell carcinoma of the lung and tested for their ability to grow in serum-supplemented medium and in serum-free medium supplemented with hydrocortisone, insulin, transferrin, estrogen, and selenium (HITES). The tumor cells replicated in 14 of 15 cases (93%) in the HITES medium and in 10 of 15 cases (67%) in the serum-supplemented medium. The neoplastic origin of the cells growing in the HITES medium was confirmed by standard cytologic criteria, by DNA content analysis using flow cytometry, and by their ability to form colonies in agarose and tumors in athymic nude mice. While the tumor cells had very similar morphologies in both media, the serum-free medium did not support the growth of nonmalignant stromal cells, and essentially pure cultures of replicating tumor cells were obtained 7-10 days after plating. The selectivity of the HITES medium was demonstrated by the failure of cells to grow in 20 specimens cytologically negative for small cell carcinoma and in 9 of 10 specimens containing other tumor types (including other types of lung cancer). The results demonstrate that a chemically defined medium, determined by work on tissue culture-adapted human tumor lines, can support the selective growth of tumor specimens obtained directly from patients. Such selective formulas are probably specific for different tumor types and thus could be used for diagnosis, drug sensitivity testing in vitro, and identification of factors regulating tumor growth. All of these have direct application to patient treatment.
 ...
PMID:Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. 626 40

An experimental study was undertaken to evaluate the effects of total parenteral nutrition (TPN) on tumor growth in rats. Sato lung cancer was transplanted subcutaneously in male Donryu rats. Two weeks after inoculation, experimental animals were divided into three groups: Group I (5% G); Group II (21% G, 4% A.A; TPN) received intravenous infusion through cervical vein; Group III rats were maintained on a regular diet. All of the animals were killed on the eighth day. There was a significant increase in tumor volume and tumor weight in both G-II (7.3 +/- 3.9 cm3, 8.7 +/- 6.3 g) and G-III (7.4 +/- 4.6 cm3, 9.7 +/- 5.4 g), as compared with G-I (3.3 +/- 1.4 cm3, 3.7 +/- 1.9 g). In morphometric studies, an average area of tumor cell in G-II was 267 +/- 172 microns2, being significantly larger than in G-I (195 +/- 95 microns2) or G-III (185 +/- 93 microns2). The nuclear diameter of tumor cell was 9.9 +/- 2.2 microns in G-II, 9.2 +/- 1.9 micron in G-III, and 8.5 +/- 1.5 micron in G-I, respectively. Total water balance throughout the experimental period was +84.0 +/- 14.5 ml/100 g BW in G-II, +86.3 +/- 8.2 ml/100 g BW in G-III, and +44.8 +/- 22.5 ml/100 g body weight in G-I, respectively. Increased tumor volume and tumor weight found in G-II may not be due to hyperplasia of each tumor cell, but rather due possibly to water retention in tumor tissue.
 ...
PMID:Does total parenteral nutrition (TPN) really promote tumor growth? A morphometric study. 643 77

A rat lung cancer model based on intrabronchial instillation of a tumor cell suspension has been developed for use in therapy and toxicity testing. Two tumors were used in this study, a sarcoma and an adenocarcinoma, both of which were of spontaneous origin in the strain of rats used. The inoculated tumor cells implant on the bronchiolar mucosa, forming a detectable single "primary" tumor resembling the spontaneous lung cancers arising in humans. The tumor growth is detectable by use of diagnostic radiographs, weight loss and other "clinical" signs. The tumors appear on chest radiographs 3 to 5 weeks after inoculation, and the implant rate is proportional to the number of tumor cells inoculated. Untreated animals have a median survival (after radiographic detection of the tumor) of 8 days, and die of local complications of tumor growth. When a slow growing transplantable tumor line of lung origin is developed, this model will be used to evaluate radiotherapy and chemotherapy schedules.
 ...
PMID:Development of a rat lung cancer model. 649 Apr 38

Eighty-six thoracic neoplasms, both primary and metastatic, were removed at thoracotomy from 86 patients and were tested for chemosensitivity in the clonogenic assay. Substantial tumor growth was achieved in 79% (67/86). Fifty-two percent (16/31) of the primary lung tumors and 45% (15/33) of the metastatic tumors were sensitive to at least one tested drug. Clinical correlations between in vitro chemosensitivity and in vivo response were possible in 20 patients. The assay was 83% accurate for predicting in vivo sensitivity and 86% accurate for predicting in vivo resistance. The value of the assay as it pertains to lung cancer has been demonstrated. On the basis of the results, thoracotomy is indicated in selected patients as a diagnostic procedure to obtain tissue for chemosensitivity testing.
 ...
PMID:Biopsy of thoracic neoplasms for assay of chemosensitivity. New indication for thoracotomy. 661 18

Previously reported large autopsy series have indicated that elderly patients who die of cancer are less likely to have metastatic disease than their younger counterparts. This observation could be explained if survival were shorter in the elderly population and patients died with smaller tumor burdens. The authors analyzed Medical Center Hospital of Vermont (MCHV) Tumor Registry data on primary lung cancer with respect to age. As in the reported autopsy series, at the time of diagnosis elderly patients were less likely to have metastatic disease. Further analysis was undertaken of the patients from this series who died and were autopsied at MCHV. Although the total numbers were small, survival was not shorter in the advanced age groups. The authors suggest that elderly patients have slower tumor growth and less metastatic disease, not because of earlier diagnosis and shorter survival, but because of senescent host factors that impede aggressive tumor growth and spread.
 ...
PMID:Bronchogenic cancer, metastases, and aging. 663 Aug 26

The concentrations of N-terminal peptide of type III procollagen in the sera of patients with various cancers were measured by radioimmunoassay. The mean value (with standard deviation) in the control group was 9.9 +/- 2.6 ng/ml. Serum levels exceeding 15 ng/ml were defined as positive, and it was found that 94% of 18 patients with primary liver cancer with cirrhosis, 88% of 8 patients with primary liver cancer without cirrhosis, 77% of 13 patients with metastatic liver cancer, 86% of 7 patients with recurrent breast cancer, 86% of 8 patients with colonic cancer, 75% of 8 patients with pancreatic cancer, 70% of 23 patients with stomach cancer, 51% of 35 patients with lung cancer, and 54% of 28 patients with uterine cancer showed positive levels. The concentrations showed great intersubject variations, probably reflecting the activity of tumor growth and/or invasion. The concentrations in the sera of patients with primary liver cancer with cirrhosis were generally higher than those in patients with liver cirrhosis alone or primary liver cancer without cirrhosis. This result suggested that the growth of primary liver cancer complicated by cirrhosis might be detected by serial measurements of this peptide in the serum of patients with liver cirrhosis. Present data suggested that this peptide is not cancer-specific, but assay of the peptide might be of value as an auxiliary means of detecting and monitoring various cancers, especially liver cancer.
 ...
PMID:High concentrations of N-terminal peptide of type III procollagen in the sera of patients with various cancers, with special reference to liver cancer. 673 30


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>